Highlights Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe Other stock markets 03:52:48 08/05/2024 pm IST			5-day change	1st Jan Change
90.6 ^CHF	+0.92%		+1.97%	+6.78%

06/05	NOVARTIS AG : UBS maintains a Buy rating	ZD
02/05	Health Care Flat Amid Mixed Earnings -- Health Care Roundup	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Health Care Flat Amid Mixed Earnings -- Health Care Roundup	03/05	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	03/05	MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon	02/05	MT
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat	02/05	MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET	02/05	DJ
Novartis AG to Acquire Mariana Oncology in Deal Valued Up to $1.75 Billion.	02/05	MT
News Highlights : Top Company News of the Day - Thursday at 9 AM ET	02/05	DJ
Novartis: acquisition of US-based Mariana Oncology	02/05	CF
Switzerland's Novartis to Buy US-based Mariana Oncology for $1 Billion Upfront	02/05	MT
Novartis to Buy Mariana Oncology, Pay $1 Billion Upfront	02/05	MT
Novartis AG to Acquire Mariana Oncology	02/05	MT
Novartis AG to Acquire Mariana Oncology	02/05	MT
Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business	02/05	DJ
Novartis to buy radiology specialist Mariana Oncology for $1 billion	02/05	RE
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	01/05	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04	MT
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	30/04	CI
Novartis target Morphosys multiplies losses - takeover schedule stands	30/04	DP
Morphosys says takeover by Novartis on course after report of drug safety concern	29/04	RE